GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Interest Coverage

Tourmaline Bio (Tourmaline Bio) Interest Coverage : N/A (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Tourmaline Bio's Operating Income for the three months ended in Dec. 2023 was $-6.32 Mil. Tourmaline Bio's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Tourmaline Bio Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Tourmaline Bio's Interest Coverage or its related term are showing as below:


TRML's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Tourmaline Bio Interest Coverage Historical Data

The historical data trend for Tourmaline Bio's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tourmaline Bio Interest Coverage Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Interest Coverage
No Debt N/A N/A

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial No Debt N/A N/A No Debt N/A

Competitive Comparison of Tourmaline Bio's Interest Coverage

For the Biotechnology subindustry, Tourmaline Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tourmaline Bio's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's Interest Coverage falls into.



Tourmaline Bio Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tourmaline Bio's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Tourmaline Bio's Interest Expense was $0.00 Mil. Its Operating Income was $-45.41 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.19 Mil.

GuruFocus does not calculate Tourmaline Bio's interest coverage with the available data.

Tourmaline Bio's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Tourmaline Bio's Interest Expense was $0.00 Mil. Its Operating Income was $-6.32 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.19 Mil.

GuruFocus does not calculate Tourmaline Bio's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Tourmaline Bio  (NAS:TRML) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Tourmaline Bio Interest Coverage Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Tourmaline Bio (Tourmaline Bio) Business Description

Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.